FFA
KYMR icon

Farther Finance Advisors’s Kymera Therapeutics KYMR Stock Holding History

Farther Finance Advisors’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$4.81K Sell
43
-135
-76% -$15.5K ﹤0.01% 5030
2026
Q2 		$20.4K Buy
178
+2
+1% +$172 ﹤0.01% 3952
2026
Q1 		$14.9K Buy
176
+11
+7% +$871 ﹤0.01% 3847
2025
Q4 		$12.8K Buy
165
+81
+96% +$5.47K ﹤0.01% 3743
2025
Q3 		$4.75K Sell
84
-540
-87% -$24.4K ﹤0.01% 3786
2025
Q2 		$27.2K Buy
624
+540
+643% +$18.6K ﹤0.01% 2482
2025
Q1 		$2.12K Hold
84
– – ﹤0.01% 3369
2024
Q4 		$3.38K Buy
84
+70
+500% +$3.16K ﹤0.01% 2831
2024
Q3 		$663 Buy
14
+6
+75% +$265 ﹤0.01% 3355
2024
Q2 		$248 Hold
8
– – ﹤0.01% 3450
2024
Q1 		$315 Hold
8
– – ﹤0.01% 3156
2023
Q4 		$204 Buy
+8
New +$143 ﹤0.01% 3223

Other funds holding KYMR

NAM
NorthCrest Asset Manangement Plymouth, Minnesota $4.24B AUM 32.82% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return
VCM
Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return
CIA
Cape Investment Advisory Mcdonough, Georgia $388M AUM 17.15% 1-Year Est. Return
MAM
Marquette Asset Management Minneapolis, Minnesota $766M AUM 16.04% 1-Year Est. Return

Farther Finance Advisors's KYMR Position: Q3 2026 in Review

Farther Finance Advisors reduced its Kymera Therapeutics (KYMR) stake by 76% in Q3 2026, selling an estimated $15.5K and leaving 43 shares worth $4.81K. The position accounts for ﹤0.01% of the portfolio, ranked #5030.

Farther Finance Advisors first reported a position in KYMR in Q4 2023 and has held it in 12 quarters since. The position peaked at $27.2K in Q2 2025. 7 funds tracked by Wall St. Rank hold KYMR as of Q3 2026.

  • Farther Finance Advisors held 43 shares of Kymera Therapeutics worth $4.81K as of Q3 2026.
  • Farther Finance Advisors sold 135 Kymera Therapeutics shares in Q3 2026, an estimated $15.5K.
  • Kymera Therapeutics made up ﹤0.01% of Farther Finance Advisors's portfolio in Q3 2026, its #5030 holding.
  • Farther Finance Advisors first reported a position in Kymera Therapeutics in Q4 2023 and has held it in 12 quarters since.
  • Farther Finance Advisors's Kymera Therapeutics position peaked at $27.2K in Q2 2025.
  • 7 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q3 2026.

Based on Farther Finance Advisors's 13F filing for Q3 2026, filed 8 Oct 2026.